Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.54 |
| ▸ | CDK4 | P11802 | 5/20 | 0.54 |
| ▸ | PLK1 | P53350 | 4/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 4/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CCNH | P51946 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14546731 | 0.90 | CDK2 (0.43) | CDK2CDK4PLK1KDRAURKB | |
| SCHEMBL14817436 | 0.90 | PIK3CA (0.52) | CDK2CDK4KDRAURKBSYK | |
| SCHEMBL3208140 | 0.89 | EIF2AK2 (0.53) | CDK2CDK4PLK1KDRABL1 | |
| SCHEMBL3203537 | 0.88 | CDK2 (0.51) | CDK2CDK4PLK1KDRAURKB | |
| SCHEMBL13486463 | 0.88 | CDC7 (0.47) | CDK2CDK4PLK1KDRPTK2 | |
| SCHEMBL13486460 | 0.88 | ABL1 (0.52) | CDK2CDK4SYKABL1PIK3CG | |
| SCHEMBL1412243 | 0.88 | JAK2 (0.49) | PLK1AURKBSYKABL1BCR | |
| SCHEMBL3211790 | 0.86 | ABL1 (0.44) | CDK2CDK4PLK1KDRAURKB | |
| SCHEMBL1411721 | 0.86 | ABL1 (0.45) | CDK2CDK4PLK1ABL1PIK3CA | |
| SCHEMBL3201188 | 0.86 | JAK2 (0.50) | CDK2CDK4SYKEIF2AK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404692-B2 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds | CYCLACEL LIMITED (GB) | 2013-03-26 | — | — | US | claimed |
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYCLACEL LIMITED (GB) | 2010-02-11 | — | — | US | claimed |
| EP-1940846-A2 | PYRIMIDIN-4-YL-3,4-DIHYDRO-2H-PYRROLO[1,2A]PYRAZIN-1-ONE COMPOUNDS | Cyclacel Limited (GB) | 2008-07-09 | — | — | EP | claimed |
| WO-2007042784-A2 | PYRIMIDIN-4-YL-3, 4-DIHYDR0-2H- PYRROLO [1, 2A] PYRAZIN-1-ONE COMPOUNDS | CYCLACEL LIMITED (GB) | 2007-04-19 | — | — | WO | claimed |
| US-8404692-B2 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds | CYCLACEL LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8404692-B2 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds | CYCLACEL LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8404692-B2 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds | CYCLACEL LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| EP-1940846-B9 | PYRIMIDIN-4-YL-3,4-DIHYDRO-2H-PYRROLO[1,2A]PYRAZIN-1-ONE COMPOUNDS | CYCLACEL LTD (GB) | 2012-09-12 | — | — | EP | disclosed |
| EP-1940846-B1 | PYRIMIDIN-4-YL-3,4-DIHYDRO-2H-PYRROLO[1,2A]PYRAZIN-1-ONE COMPOUNDS | CYCLACEL LTD (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYCLACEL LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYCLACEL LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYCLACEL LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| EP-1940846-A2 | PYRIMIDIN-4-YL-3,4-DIHYDRO-2H-PYRROLO[1,2A]PYRAZIN-1-ONE COMPOUNDS | Cyclacel Limited (GB) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007042784-A2 | PYRIMIDIN-4-YL-3, 4-DIHYDR0-2H- PYRROLO [1, 2A] PYRAZIN-1-ONE COMPOUNDS | CYCLACEL LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042784-A2 | PYRIMIDIN-4-YL-3, 4-DIHYDR0-2H- PYRROLO [1, 2A] PYRAZIN-1-ONE COMPOUNDS | CYCLACEL LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYP2A13, NR1I3, NR3C2 | CDK2 577/4885CDK4 657/4885PLK1 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.